✦ LIBER ✦

A multidisciplinary therapeutic approach for advanced previously untreated: Epidermoid cancer of the head and neck: Preliminary report

✍ Scribed by Muhyi Al-Sarraf; Magid H. Amer; Ganghadar Vaishampayan; John Loh; Arthur Weaver

Book ID: 103718560
Publisher: Elsevier Science
Year: 1979
Tongue: English
Weight: 358 KB
Volume: 5
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(79)90682-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Induction chemotherapy with cisplatinum,

Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck

✍ G. Fountzilas; A. Nicolaou; K. Sridhar; T. Sideras; A. Haritanti; C. Anastasakis 📂 Article 📅 1989 🏛 Springer-Verlag 🌐 English ⚖ 469 KB

Combined postoperative radiotherapy and

Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial

✍ Jean-Marl Bachaud; Jean-Marl David; Gérard Boussin; Nicolas Daly 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 530 KB

Chemotherapy as a substitute for surgery

Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the northern California oncology group

✍ Charlotte Jacobs; Don R. Goffinet; Linda Goffinet; Marsha Kohler; Willard E. Fee 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

Chemotherapy for advanced head and neck

Chemotherapy for advanced head and neck cancer with the combination adriamycin, cyclophosphamide, and cis-diamminedichloroplatinum (II): Preliminary assessment of a one-day vs. three-day drug regimen

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 3 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad

cis-diamminedichloroplatinum (II) and bl

cis-diamminedichloroplatinum (II) and bleomycin induction chemotherapy as an adjuvant to conventional treatment modalities in advanced head and neck cancer preliminary report of the results of a non-randomized trial and control series

✍ Alptekin Ucmakli; Waun Ki Hong; Stanley M. Shapshay; M. Stuart Strong; Charles W 📂 Article 📅 1978 🏛 Elsevier Science 🌐 English ⚖ 182 KB